Table I.
Clinical characteristics and treatments
| Case | 1 | 2 | 3 |
|---|---|---|---|
| History of atopy or AD | No | No | No |
| Biologic in use when AD reaction occurred | Tildrakizumab | Ustekinumab | Ixekizumab |
| Previous failed therapies for psoriasis or Crohn's disease | Triamcinolone 0.1% cream Calcipotriene 0.005% cream Adalimumab Etanercept Ustekinumab Secukinumab |
Adalimumab Infliximab |
Calcipotriene 0.005 % ointment Phototherapy Halobetasol propionate/tazarotene 0.01%/0.045% lotion Triamcinolone 0.5% cream Adalimumab Secukinumab Ustekinumab |
| PASI before current biologic | 8.4 | Not applicable (patient on ustekinumab for Crohn's disease) | 9 |
| PASI at follow-up∗ | 1.2 | Not applicable (patient on ustekinumab for Crohn's disease) | 0.6 |
| Time between initiation of biologic and appearance of eczematous reaction (months) | 12 | 12 | 2 |
| Localization of eczematous reaction | Hands, legs | Eyelids, back, abdomen | Hands |
| EASI at baseline | 9.2 | 9.4 | 3.6 |
| Peak pruritus NRS | 7 | 9 | 6 |
| AD therapies trialed before dupilumab† | Crisaborole 2% ointment Triamcinolone 0.1% ointment Clobetasol 0.05% ointment Tacrolimus 0.1% ointment |
Flurandrenolide tape 4 mcg/cm2 tape daily as needed Hydrocortisone 2.5% cream Monthly Kenalog injections (total of 6 months) Crisaborole 2% ointment Triamcinolone 0.1% ointment Tacrolimus 0.1% ointment |
Crisaborole 2% ointment Halobetasol propionate 0.01% lotion Triamcinolone 0.1% ointment Tacrolimus 0.1% ointment |
| EASI at follow-up‡ | 0 | 0 | 0 |
| Duration of dual biologic therapy at time of manuscript preparation (months) | 7 | 12 | 9 |
AD, Atopic dermatitis; EASI, eczema area and severity index; NRS, numerical rating scale; PASI, psoriasis area and severity index.
∗
Mean follow-up time of 3 months.
†
Duration and frequency of topical use was 2-4 weeks, applied twice a day, unless specified otherwise.
‡
Mean follow-up time of 4.6 months.